SynthesisDrug safety2023
Factors Associated with Underreporting of Adverse Drug Reactions by Health Care Professionals: A Systematic Review Update.
Synthesis in Drug safety, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 92 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
92 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Empowering citizens to spontaneously report suspected adverse drug reaction: Systematic literature review of interventions and their impact.British journal of clinical pharmacology · 2026Pooled it
- Pooled it
- Effectiveness of the modified TaWai mobile application for reporting adverse drug reaction in Lao PDR: a cluster randomized controlled trial.Scientific reports · 2024Trial
- Reported Dosing-Related Medication Errors Involving Systemic Antibiotics in the Brazilian Pharmacovigilance Database (2018-2025): Distribution Across the WHO AWaRe Classification.Pharmacoepidemiology and drug safety · 2026Article
- Consumers' experiences and perspectives on reporting adverse drug reactions using digital tools: a qualitative study.International journal of clinical pharmacy · 2026Article
- Reporting of suspected adverse drug reactions: a systematic review comparing clinical settings and pharmacovigilance systems.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Article
- Reporting patterns of adverse drug withdrawal events using individual case safety reports in the FAERS and Eudravigilance databases.Exploratory research in clinical and social pharmacy · 2026Article
- Leveraging Administrative Health Data to Capture Rare Adverse Drug Reactions: Identifying Pediatric Patients With Trimethoprim-Sulfamethoxazole Acute Respiratory Distress Syndrome.Pharmacology research & perspectives · 2026Article
- Practice, knowledge and attitude of physicians and pharmacists towards the spontaneous reporting system of adverse drug reactions in Switzerland.British journal of clinical pharmacology · 2026Article
- Patient-Level Risk Characterization of Drug-Associated Hidradenitis Suppurativa Using Machine Learning.medRxiv : the preprint server for health sciences · 2026Article
- Metabolic and Inflammatory Adverse Drug Reactions Associated with Amlodipine: A Descriptive and Disproportionality Analysis of EudraVigilance Reports.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Posterior Circulation Ischemic Stroke Occurring After ChAdOx1 nCoV-19/AZD1222 Vaccination Without Evidence of Vaccine-Induced Immune Thrombotic Thrombocytopenia: A Case Report and Focused Narrative Review.Journal of clinical medicine · 2026Review
- Are Traditional Registries Becoming Obsolete in the Modern Digital Health Ecosystem?Journal of medical Internet research · 2026Article
- Article
- Secondary Restless Legs Syndrome during psychopharmacological treatment: real-world evidence from a multinational pharmacovigilance program.The international journal of neuropsychopharmacology · 2026Article
- Risks Associated with 5α-Reductase Inhibitor Use: Analysis of Adverse Drug Reactions Reported to EudraVigilance.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Patterns of Spontaneous Adverse Drug Reaction Reporting in Germany From 2012 to 2021.Pharmacology research & perspectives · 2026Article
- Review
- A Feasibility Assessment of the FDA Adverse Event Reporting System for the Detection of Cannabis-Related Safety Signals.Pharmacoepidemiology and drug safety · 2026Article
32 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionUnderreporting is a major limitation of the voluntary reporting system of adverse drug reactions (ADRs). A 2009 systematic review showed the knowledge and attitudes of health professionals were strongly related with underreporting of ADRs.
objectiveOur aim was to update our previous systematic review to determine factors (sociodemographic, knowledge and attitudes) associated with the underreporting of ADRs by healthcare professionals.
methodsWe searched the MEDLINE and EMBASE databases for studies published between 2007 and 2021 that met the following inclusion criteria: (1) published in English, French, Portuguese or Spanish; (2) involving health professionals; and (3) the goal was to evaluate factors associated with underreporting of ADRs through spontaneous reporting.
resultsOverall, 65 papers were included. While health professional sociodemographic characteristics did not influence underreporting, knowledge and attitudes continue to show a significant effect: (1) ignorance (only serious ADRs need to be reported) in 86.2%; (2) lethargy (procrastination, lack of interest, and other excuses) in 84.6%; (3) complacency (the belief that only well tolerated drugs are allowed on the market) in 46.2%; (4) diffidence (fear of appearing ridiculous for reporting merely suspected ADRs) in 44.6%; and (5) insecurity (it is nearly impossible to determine whether or not a drug is responsible for a specific adverse reaction) in 33.8%, and the absence of feedback in 9.2%. In this review, the non-obligation to reporting and confidentiality emerge as new reasons for underreporting.
conclusionsAttitudes regarding the reporting of adverse reactions continue to be the main determinants of underreporting. Even though these are potentially modifiable factors through educational interventions, minimal changes have been observed since 2009. CLINICAL TRIALS REGISTRATION: PROSPERO registration number CRD42021227944.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.